Safety, Immunogenicity and Efficacy of Modified Vaccinia Ankara (MVA) Against Dryvax Challenge in Vaccinia-Naive and Vaccinia-Immune Individuals
Year of Publication
Parrino, J; McCurdy, LH; Larkin, BD; Gordon, IJ; Rucker, SE; Enama, ME; Koup, RA; Roederer, M; Bailer, RT; Moodie, Z; Gu, L; Yan, L; Graham, BS; The VRC 201/203 Study Team
Antibody Formation/immunology; CD8-Positive T-Lymphocytes/immunology; Smallpox Vaccine/administration & dosage/adverse effects/immunology Vaccinia virus/immunology; Smallpox/prevention & control
Modified vaccinia Ankara (MVA) was evaluated as an alternative to Dryvax in vaccinia-naive and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or placebo followed by Dryvax challenge at 3 months. Two or more doses of MVA prior to Dryvax reduced severity of lesion formation, decreased magnitude and duration of viral shedding, and augmented post-Dryvax vaccinia-specific CD8(+) T cell responses and extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses.